etoposide oral / Generic mfg. - LARVOL DELTA

Maintenance zanzalintinib with oral etoposide following high-dose chemotherapy in patients with relapsed metastatic germ-cell tumor (GCT). (ASCO-GU 2026) - P1/2 | "Background: While most patients (pts) with metastatic GCTs are cured with first line cisplatin-based chemotherapy, 20-30% relapse after treatment. This study is currently enrolling patients. Clinical trial information: NCT06937866."

Clinical • Metastases • Genito-urinary Cancer • Germ Cell Tumors • Oncology • Testicular Cancer • AXL • KDR • MET

Randomized phase II trial of maintenance oral etoposide versus observation following high-dose chemotherapy and peripheral blood stem cell transplant in relapsed non-seminomatous germ cell tumors. (ASCO-GU 2026) - P2 | "Eligible patients are adults with metastatic NSGCT who have experienced progression after first-line cisplatin-based chemotherapy. All participants will complete two tandem cycles of HDCT using the Indiana carboplatin/etoposide protocol...Accrual and follow-up are ongoing. Clinical trial information: NCT04804007."

Clinical • P2 data • Genito-urinary Cancer • Germ Cell Tumors • Oncology • Testicular Non-seminoma • Testicular Seminoma

Aumolertinib plus oral etoposide (Lastet) as first-line treatment for EGFR-mutated, locally advanced or metastatic non-small cell lung cancer (NSCLC): The multicenter, phase II EVOLUTION study (ELCC 2026) - P2 | "No new safety signals were identified compared with the established profiles of each individual drug.Conclusions The all-oral combination of aumolertinib and etoposide demonstrated promising antitumor activity and a manageable safety profile in treatment-naive EGFR-mutated NSCLC. This regimen offers a potential convenient, outpatient-based therapeutic strategy worthy of further validation."

Clinical • Metastases • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Title Results of the Safety Run-In Part of the TUC-TOC Phase II trial (NCT05955170): Tucatinib in combination with Oral Etoposide (VP16) - Trastuzumab in Patients with metastatic HER2-positive Breast Cancer (HER2+ mBC) (ESMO-BC 2026) - P2 | No abstract available

Clinical • Combination therapy • Metastases • P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Retraction: A phase II, single-arm study of apatinib and oral etoposide in heavily pre-treated metastatic breast cancer. (PubMed, Front Oncol) - "[This retracts the article DOI: 10.3389/fonc.2020.565384.]."

Journal • P2 data • Breast Cancer • Oncology • Solid Tumor

Gut bacterial O-demethylation modulates systemic exposure to oral etoposide. (PubMed, Gut Microbes) - "Comparative pharmacokinetic analysis of orally administered etoposide in control and antibiotic-treated mice showed that systemic exposure to etoposide increased 1.9-fold, while M1 exposure decreased 3.7-fold in antibiotic-treated mice, suggesting that gut microbial O-demethylation is a significant determinant of etoposide metabolism and disposition. Collectively, our study reveals the prevalence of gut bacteria with O-demethylation activity, illustrates the contribution of gut microbial O-demethylation to altering drug efficacy and toxicity with the model drug etoposide, and provides a knowledge basis for in-depth characterization of other drugs identified as being susceptible to gut microbial O-demethylation."

Journal • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study (clinicaltrials.gov) - P2 | N=47 | Not yet recruiting | Sponsor: The Third Affiliated Hospital of Harbin Medical University

New P2 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Pyrotinib combined with metronomic etoposide in heavily pretreated HER2-positive metastatic breast cancer: a single-arm, phase II study. (PubMed, BMC Cancer) - P2 | "The combination of pyrotinib with metronomic oral etoposide has achieved promising clinical benefits in heavily pretreated HER2-positive MBC, with acceptable and manageable toxicity."

Journal • Metastases • P2 data • Breast Cancer • Hematological Disorders • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Pain • Solid Tumor • HER-2

A single-arm, open-label, single-center, exploratory phase II clinical study of etoposide capsules combined with bevacizumab and avelumab in the treatment of platinum-resistant or platinum-refractory ovarian cancer (ChiCTR) - P2 | N=33 | Not yet recruiting | Sponsor: Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center

New P2 trial • Platinum resistant • Oncology • Ovarian Cancer • Refractory Ovarian Cancer • Solid Tumor • MUC16

Safety and Efficacy Analysis of Oral Etoposide Combined With Anlotinib and Envafolimab in First-line Treatment of Elderly Patients With Small Cell Lung Cancer/ Open-label, Single-arm, Exploratory Phase II Clinical Study (clinicaltrials.gov) - P2 | N=30 | Active, not recruiting | Sponsor: Tianjin Medical University Cancer Institute and Hospital | Trial completion date: Dec 2025 ➔ May 2026

Trial completion date • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

A phase II clinical study on the efficacy and safety of anlotinib combined with oral etoposide capsules as first-line treatment for extensive-stage small cell lung cancer (ESSCLC) (ChiCTR) - P=N/A | N=39 | Not yet recruiting | Sponsor: The Pearl River Hospital of Southern Medical University; The Pearl River Hospital of Southern Medical University

New trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

FUS Etoposide for DMG (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: Columbia University | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial primary completion date • Brain Cancer • Diffuse Intrinsic Pontine Glioma • Diffuse Midline Glioma • Glioma • Oncology • Solid Tumor

Curative Surgery Following Induction Chemotherapy for Sinonasal Small Cell Neuroendocrine Carcinoma With Contraindication to Radiotherapy. (PubMed, Anticancer Res) - "This case highlights the feasibility of a radiation-free sequential strategy integrating induction chemotherapy, surgery, and adjuvant oral chemotherapy in selected patients with locally advanced sinonasal SCNEC who are ineligible for standard regimens."

Journal • Endocrine Cancer • Nasopharyngeal Carcinoma • Neuroendocrine Carcinoma • Oncology • Solid Tumor

Oral VP16 combined with ATRA and realgar-indigo naturalis formula as complete oral induction regimen is an fast,safe and effective regimen during induction to reduce mortality in high-risk acute promyelocytic leukemia (ASH 2025) - P4 | "Current international and Chinese guidelines recommend all-trans-retinoic acid (ATRA) plus arsenic tri-oxide, combined with either an anthracycline or cytarabine...To evaluate the efficacy and safety of oral etoposide combined with ATRA and RIF in high-risk APL, we have initiated a single-arm, prospective cohort study (ChiCTR2100053926). Once high-risk APL was suspected, ATRA 25mg/m 2 /day, hydroxyurea (Hu) and oral VP16 100-150 mg/day were given simultaneously...Nine (27.3%) pts used venetoclax to combinate with VP 16 with a median dose of 100 (50-300) mg... Compared with historical cases, oral VP16, instead of intravenous cytoreductive agent, in combination with ATRA and RIF as complete oral induction in high-risk APL, could control leukocytosis effectively and safely. Meanwhile high CR rate, RFS and OS could also achieve. In addition, this regimen is convenient for pts to receive fast and professional treatment as soon as possible without the limitation of space."

Acute Promyelocytic Leukemia • Cerebral Hemorrhage • Gastroenterology • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • Novel Coronavirus Disease • CD34 • FLT3

Adult-onset non-langerhans histiocytosis with multisystem involvement and sustained remission on immunochemotherapy (ASH 2025) - "The patient was treated with oral etoposide 200 mg for 3 days every 21 days, in combination with oral prednisone, over the course of one year. Recognition of characteristic histopathologic and immunohistochemical profiles, in combination with imaging to exclude alternative diagnoses, is essential for accurate classification. Early recognition and initiation of immunochemotherapy can lead to durable remission, even in cases with multisystem involvement."

Clinical • CNS Disorders • Endometrial Cancer • Esophageal Cancer • General Anxiety Disorder • Hepatology • Hypertension • Langerhans Cell Histiocytosis • Mental Retardation • Mood Disorders • Rare Diseases • Respiratory Diseases • Solid Tumor • CD1a • CD68 • TNFRSF8

Oral etoposide vs intravenous daunorubicin plus ATRA-RIF as induction therapy for low-risk acute promyelocytic leukemia: A phase II randomized controlled Trial (ASH 2025) - P=N/A | "The data suggest a potential link between reduced cytoreductive dosingand increased relapse risk, while maintaining a manageable safety profile. Ongoing studies withextended follow-up will further define long-term outcomes."

Clinical • P2 data • Acute Promyelocytic Leukemia • Hematological Malignancies • Leukemia • CD34 • FLT3 • NCAM1 • PML

Safety and Efficacy Analysis of Oral Etoposide Combined With Anlotinib and Envafolimab in First-line Treatment of Elderly Patients With Small Cell Lung Cancer/ Open-label, Single-arm, Exploratory Phase II Clinical Study (clinicaltrials.gov) - P2 | N=30 | Active, not recruiting | Sponsor: Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting ➔ Active, not recruiting | Trial completion date: May 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2023 ➔ Dec 2025

Enrollment closed • Trial completion date • Trial primary completion date • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

REAL-WORLD EXPERIENCE OF CABOZANTINIB MONOTHERAPY IN RELAPSED OR REFRACTORY OSTEOSARCOMA AND EWING SARCOMA: A SINGLE-CENTRE AUSTRALIAN STUDY (CTOS 2025) - "Following progression (n=9), one patient received oral etoposide, one received palliative radiation therapy, the remainder (n=7) did not receive further anti-cancer therapy... Our real-world data showed that CBZ monotherapy has clinically meaningful activity in osteosarcoma and ES, with acceptable toxicities. Validation in larger cohorts is warranted."

Clinical • Monotherapy • Real-world • Real-world evidence • Ewing Sarcoma • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

A Completely Oral Regimen Including Oral Etoposide As Cytoreductive Chemotherapy Combined with All Trans Retinoic Acid and Oral Arsenic for Induction Therapy in Patients with High-Risk APL:Comparable to Intravenous Cytoreductive Therapy (ASH 2023) - "A completely oral, efficient and safe induction regimen including oral VP16 as cytoreductive chemotherapy combined with ATRA and RIF is more convenient to administer for patients with high-risk APL."

Clinical • Acute Promyelocytic Leukemia • Cerebral Hemorrhage • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Novel Coronavirus Disease • Oncology • Respiratory Diseases

Cytoreductive Chemotherapy in Induction Therapy Plays a Key Role in the Prognosis of Patients with Low-Risk Acute Promyelocytic Leukemia (ASH 2023) - P=N/A | "Cytoreduction therapy, including hydroxycarbamide, anthracyclines and cytarabine during induction therapy was administrated based on the 2018 Chinese APL guidelines. In summary, the present study indicated that cytoreductive chemotherapy had a dual effect of both cytoreduction and prevention of relapse in low-risk APL. Oral etoposide as cytoreduction therapy combined with oral ATRA plus RIF is expected to be a regimen with low relapse, good tolerance and great convenience. A prospective, randomized, controlled, interventional study on oral etoposide versus intravenous daunorubicin for cytoreductive chemotherapy in induction therapy in patients with low-risk APL is now going on (NCT05832320)."

Clinical • Acute Promyelocytic Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Novel Coronavirus Disease • Oncology • PML • RARA

Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1 | N=10 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Oct 2025 ➔ Sep 2026 | Trial primary completion date: Oct 2025 ➔ Sep 2026

Trial completion date • Trial primary completion date • B Cell Lymphoma • Burkitt Lymphoma • Diffuse Large B Cell Lymphoma • Gene Therapies • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD34

Maintenance Zanzalintinib With Etoposide After HDCT in GCT (clinicaltrials.gov) - P1/2 | N=38 | Recruiting | Sponsor: Indiana University | Not yet recruiting ➔ Recruiting | Trial completion date: Mar 2032 ➔ Sep 2031

Enrollment open • Trial completion date • Germ Cell Tumors

Adebrelimab combined with etoposide plus platinum followed by adebrelimab and etoposide soft capsules for maintenance treatment of extensive-stage small cell lung cancer: a single-arm phase II trial (ChiCTR) - P4 | N=40 | Recruiting | Sponsor: Jiangsu Cancer Hospital; Jiangsu Cancer Hospital

New P4 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

DEFYING THE ODDS: A LONG-TERM SURVIVAL WITH DIFFUSE MIDLINE GLIOMA H3K27M MUTATION. (SIOP 2025) - "To enhance the immune effect, a combination of bevacizumab and pembrolizumab was administered, leading to neurological improvement and tumor reduction. Maintenance therapy with irinotecan, bevacizumab, and temozolomide were also administered...She underwent reirradiation (25 Gy), along with oral etoposide and valproic acid until tumor progression in February 2020... The exceptional long-term survival of this child may reflect the benefits of multi-agent treatment, along with the integrative palliative care and family support provided in managing DIPG from the time of diagnosis."

IO biomarker • Brain Cancer • Diffuse Midline Glioma • Glioma • Palliative care • Pediatrics • Solid Tumor

HIGH-RISK MEDULLOBLASTOMA IN CHILDREN OLDER THAN FOUR YEARS OLD: A PROSPECTIVE ANALYSIS OF OUTCOME WITH CRANIOSPINAL RADIATION AND METRONOMIC THERAPY (SIOP 2025) - " Prospective study -Patients were treated with CSI 36Gy, concomitant carboplatin followed by maintenance CT cisplatin/cyclophosphamide-based and metronomic CT (oral etoposide, cyclophosphamide, fenofibrate and celecoxibe) for one year. We report the outcome of children with HR-MB treated in an upper middle-income country with CSI, maintenance and metronomic CT highlighting the potential role of metronomic CT in improving survival in this high-risk population."

Clinical • Brain Cancer • Medulloblastoma • Solid Tumor • MYC • MYCN